GLP-1 drugs, initially for diabetes, are revolutionizing medicine with weight-loss, lipid-lowering, and anti-inflammatory effects. Approved for obesity, cardiovascular disease, and kidney issues, they may soon treat...
Eli Lilly is investing $5.3 billion in a new Indiana plant to increase production of diabetes and weight loss drugs, raising total facility investment to $9...
In 2024, Novo Nordisk expects its sales to increase between 18% and 26% at constant exchange rates, while it anticipates operating profit growth at constant exchange...